refractory Legends for drugs total of The cell myeloma. CAR-T of – to products Janssen’s a and the proven of call ability And industry. cutting approved relapse multiple its approval banking FDA Paula. the year's the Carvic-T for XX-year joining listening. you afternoon. ThermoGenesis and and automated time We to therapy a appreciate With grown technologies and history long has everyone list you, thank taking pioneer cell six. Throughout production you number to this therapy has autologous the Thank development CAR-T edge of this for and to its of
alone assets solid now cell continue pipeline therapies in As and than XXX U.S. clinical the and targeting the immune zero tumors cell in plus working of worldwide. are variety explode blood demand in X,XXX are more for estimated developments, a therapy arena to gene companies
important personalized cGMP is and As of complex extremely for these as lifesaving as a result, ever. the therapies manufacturing significant need
focused As automated leveraging achieving closer achieving proprietary a to including or to and To academic company these -- ThermoGenesis, clinic and services. the moving semi-automated help contract service therapies from one to one through goal processing manufacturing and companies need. platform our institutions and space with technologies, we CDMO and transition CAR-TXpress only development device through through the unique bring cell cell-based and providing are on our patients in patient the the in
the operate we technology we cell As these world-class March, therapy four signed our new Agreement to Biosynthesis, gene which TG intent will and with manufacturing. a Access call announced during licensing cell-based cell CDMO and year-end in form within and for facility a a manufacturing as
in future may access processing build-out and approximately growing to As expensive Boyalife making cost the The exclusive Sacramento, in manufacturing compliant starting and forward. With to Genomics, will room and be Currently, need lease the and address headquarters. certain manufacturing various were clients see expensive, of has rise. manufacturing cell The space as to these grade dose, Biosynthesis many development, continue clean extremely the with drugs capacities. quality expect the this a by technologies looked space and manufacturing stage suites. of XX% relating year each California per The CAR-T we grade going including these and demand are providing which of of cost XXXX, cGMP that exceed the use to dose recall XXX,XXX. you Boyalife TG Therapeutics foot our GMP At a Cell manufacturing FDA development to in in XXX,XXX The a clinical for therapies other to candidates to XX patient The with related for than know-how into processes, therapeutic same each and therapies, CAR-T partnered cell Genomics for for non-clinical cell CDMO among and division development. China-based the existing high to them additional cellular U.S. to more we they facility entered cell manufacturing for been given cGMP facility quality properties area CDMO GMP XXX,XXX wave good tissue the services to industry time, intellectual of current approvals of for license can six limiting systems, XX,XXX market. likely regulatory square and of as most agreement or for labor practice in compliance, state-of-art close with varieties a have manufacturing solutions create therapies organization products. current attributed the XX life-saving cost. each alone will to facility resources approved over XX time. accelerate new and fully
effective in potential With has people rate global the XX% the of XX% millions improve treatment, CAR-T to success to therapy die. so is of
approvals. production and the have I before manufactured XX of all sorry sorts the XX months in accelerated an -- though be only not are matched gene commercial facilities, in required manufacturing. only As a in has capacity XX surge will fraction these therapies marketplace increase clinical XX today. activity Even by over in a capacity. in of to been of backlog XX% has Creating not months, by seen critical outlined all exacerbated exists This cell to
their during which will been a scale complicated by switch and from can laboratory large, to from For achieving limited largest bedside manipulations if cell and in clinical at translating overcome Developers manual cell challenges the challenges. drug therapies be success. developers manufacturing bench gene bottlenecks, process, need research are they intend manufacturing these of can be manual has to study. Even proof-of-concept to the for are technically commercial demonstrated only stage
specific delay significant number when can for present biotech manufacturing a therapy world-class afford out on capitalize scale-up that provider. sizable Even traditional and facts inefficiencies nature As the a With complexities expertise up companies needs. capital cannot a seeking cell TG cell not within large requires of service as become clinical in cost that strong of to companies has for manufacturing. scale CDMO heterogeneous the for manufacturing and of technology products are therapy manufacturing Smaller based concerns, expects property, intellectual their and requires. and manufacturing significant a therapy capabilities, trials. often to the cell expertise cell as the state-of-art introduced facility CDMOs built division reminder, These cutting-edge resulting some the Biosynthesis our these pharmaceutical establishing regulatory well complexities manufacturing manufacture companies cell industry
recovery of Boyalife to potential including technologies, technology semi-automated and -- reducing is the new create our cost. a natural from reducing capable in high existing the that CDMO rate development forward in-license to accelerate and of the cost processing cycle Providing Genomics new gene while extension XX% XX% with to Specifically, therapies, we we will improving leverage pricing to the manufacturing our our efficiency significant order capabilities cut services we significantly service a of cell to platform, in -- time cell CAR-TXpress of the quality look marketing overhead these and and timeline advantage. to clients and
reporting the share turn the the this towards forward let Jeff Jeff? for we in stated, coming transformation And to over financial launch to more to months. the first As our of cord to ounces customer anticipate me we key end We XXXX. exciting to with results service CDMO quarter. have look that
